Arteris - Earnings Call - Q2 2025

Executive Summary

• Q2 2025 delivered revenue at the top end of guidance ($16.50M, +13% YoY) and record KPIs (ACV+royalties $69.1M; RPO $99.3M, +28% YoY), but EPS was slightly below consensus as higher OpEx—largely FX-driven—offset gross-margin strength.
• Versus S&P Global consensus*, revenue was a small beat ($16.50M vs $16.35M*), while Primary EPS missed modestly (-$0.11 vs -$0.0975*); EBITDA was below consensus due to operating spending and FX *.
• Guidance: Q3 revenue $16.8–$17.2M and FY 2025 revenue $66–$70M were reiterated/tightened; FY non-GAAP operating loss widened to $10.5–$15.5M (from $7.0–$14.0M prior), citing FX headwinds.
• Strategic catalysts: AMD licensed FlexGen for high-performance AI chiplets; Arteris expanded multi-die/UCIe support and launched Magillem Packaging—strengthening AI and chiplet positioning and likely investor focus on medium-term ACV and RPO trajectory.

What Went Well and What Went Wrong

• What Went Well

  • Record ACV+royalties ($69.1M) and RPO ($99.3M), underscoring demand and backlog visibility; CEO: “record Annual Contract Value plus royalties... RPO... year-over-year increase of 28%”.
  • Strategic wins: AMD licensed FlexGen “for high-performance data transport for its chiplets powering AI” across a broad product set; CEO highlighted FlexGen as “breakthrough technology” recognized with an AI Breakthrough Award.
  • Platform expansion: broadened UCIe/AMBA support, EDA collaborations (Synopsys/Cadence), and RISC‑V partnerships; launch of Magillem Packaging to automate IP packaging for chiplets/SoCs.

• What Went Wrong

  • EPS/EBITDA missed consensus* despite revenue beat, reflecting higher non-GAAP OpEx from FX; CFO: “OpEx is currently running higher... as a result of the weaker U.S. Dollar” *.
  • Operating loss widened YoY (GAAP -$8.25M vs -$7.44M), with elevated R&D and sales investment to support growth and new product development.
  • Free cash flow turned negative in Q2 (-$2.84M) versus positive in Q1, tied to working-capital timing and capital purchases.

Transcript

Speaker 5

Good afternoon, everyone, and welcome to the Arteris second quarter 2025 earnings call. Please note that this call is being recorded and simultaneously webcast. All material contained in the webcast is sole property and copyright of Arteris, Inc. with all rights reserved. For opening remarks and introductions, I will now turn the call over to Erica Mannion of Sapphire Investor Relations. Please go ahead.

Speaker 1

Thank you, and good afternoon. With me today from Arteris are Charlie Janac, Chief Executive Officer, and Nick Hawkins, Chief Financial Officer. Charlie will begin with a brief review of the business results for the second quarter ended June 30, 2025. Nick will review the financial results for the second quarter, followed by the company's outlook for the third quarter and the full year of 2025. We will then open the call for questions. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements are based on management's current expectations and assumptions and involve material risks and uncertainties that could cause actual results or events to differ materially from those anticipated, and you should not place undue reliance on forward-looking statements.

Additional information regarding these risks, uncertainties, and factors that could cause actual results to differ appear in the press release Arteris issued today and in the documents and reports filed by Arteris from time to time with the Securities and Exchange Commission. Please note, during this call, we will cite certain non-GAAP measures, including, among others, non-GAAP net loss, non-GAAP net loss per share, and free cash flow, which are not measures prepared in accordance with U.S. GAAP. These non-GAAP measures are presented as we believe that they provide investors with a means of evaluating and understanding how the company's management evaluates the company's operating performance. These non-GAAP measures should not be considered in isolation from, as substitutes for, or superior to financial measures prepared in accordance with U.S. GAAP.

A reconciliation of these non-GAAP measures to the nearest GAAP measure can be found in the press release for the quarter ended June 30, 2025. In addition, for a definition of certain of the key performance indicators used in this presentation, such as annual contract value, confirmed design starts, and remaining performance obligations, please see the press release for the quarter ended June 30, 2025. These key performance indicators are presented for supplemental informational purposes only, should not be considered a substitute for financial information presented in accordance with GAAP, and may differ from similarly titled metrics or measures used by other companies, securities analysts, or investors. Listeners who do not have a copy of the press release for the quarter ended June 30, 2025 may obtain a copy by visiting the Investor Relations section of the company's website.

In addition, management will be referring to Q2 2025 earnings presentation, which can be found in the Investor Relations section of the company's website under the Events and Presentations tab. Now, I will turn the call over to Charlie.

Speaker 6

Thank you, Erica, and thanks to everyone for joining us on our call today. In the second quarter of 2025, we achieved record annual contract value plus royalties of $69.1 million. We exited the quarter with $99.3 million in remaining performance obligations, or RPO, highlighting the growing demand for our system IP technology. During the second quarter, we saw increased adoption, particularly in enterprise computing and automotive applications, driven largely by proliferation of AI computing, where the speed and reliability of data movement enabled by Arteris is paramount. One of these strategic wins was AMD, a global leader in high performance in adaptive computing and a top 10 semiconductor company by revenue, which signed an agreement to utilize Arteris FlexGen Smart Network on Chip IP, a technology we announced earlier this year.

FlexGen will aim to provide high-performance data transport in AMD chiplets, powering AI across AMD's broad portfolio, which spans from data centers to edge and end devices. It will also be used in combination with AMD Infinity Fabric Interconnect, underscoring the increasing complexity of modern SoCs and chiplet-based architectures, which now require multiple, highly specialized interconnects or NoCs. In addition to the AMD relationship, we now have over two dozen FlexGen installations at multiple customers and anticipate that this product will contribute to our revenue over time. We believe FlexGen is a breakthrough technology in terms of proactivity and optimization of SoC data movement. I'm proud that Arteris was recently recognized in the eighth annual AI Breakthrough Awards, with FlexGen winning the AI Engineering Innovation Award from among the over 5,000 global nominations.

FlexGen was recognized for its ability to successfully automate critical aspects of NoC IP creation, ensuring rapid, correct-by-design interconnect fabrics that optimize performance and efficiency of AI-driven SoCs. Another recent AI-related customer win was Railchip, a fabless semiconductor provider that specializes in developing data center ASICs and processors for high-bandwidth applications, including cloud servers, interconnect computing, and blockchain computing, among others. As the semiconductor industry accelerates efforts to increase performance and efficiency, especially driven by AI workloads, we are seeing a growing shift from traditional monolithic chips toward multi-die or chiplet architectures in the AI era. Consequently, during the second quarter, we announced an expansion of our multi-die solution, which we believe delivers further foundational technology for rapid chiplet-based innovation.

This includes broader standard support for the Universal Chiplet Interconnect Express, or UCIe, collaboration and extended support for ARM/AMBA protocols, chiplet interface collaborations with Synopsys and Cadence, as RISC-V ecosystem support with partners such as Andes, SiFive, and Tenstorrent. Moreover, the Arteris expanded multi-die solution has been developed in close partnership with key customers who are increasingly designing chiplets such as Renesas. For example, Arteris technology is used to provide underlying data transport and connectivity in the fifth generation of the ARCAR automotive silicon developed by the High Performance Computing SoC business unit. Arteris multi-die solutions help Renesas deliver on the integration and scalability offered by multi-die SoCs as AI applications push the limit of performance and power efficiency. Lastly, as the number of chiplets in multi-die SoCs increases, so does the underlying number of individual IP blocks.

As such, it becomes increasingly important to properly and reliably package and prepare hundreds or even thousands of these IP components for effective integration and reuse across SoCs, chiplets, and complex IP subsystems. To capitalize on this trend in the second quarter, we announced Magillem Packaging, a new software product designed to automate IP packaging to simplify and speed up the process of assembling silicon chiplets and chips. Utilizing the latest version of the IEEE 6085 IP-XACT standard, Magillem Packaging is designed to work seamlessly with industry tools and silicon IP with the goal of helping companies meet increasing design demands while reducing costly errors and delays associated with integrating an ever-growing number of IP blocks and the associated rising system complexity.

We believe the scale and scope of our opportunity remain robust, supported by our current products and strong product pipeline of new silicon system IP technologies, as well as growing relationships with the largest and most advanced electronics companies in the world. Our customers continue to innovate in exciting high-growth areas, including across multiple applications of AI from data centers to the edge, autonomous driving, advanced communications, consumer, and industrial use cases. While we continue to diligently monitor the current global economic uncertainty, this did not lead to any deal cancellations or delays in the second quarter. In addition, we are seeing opportunities for customers to accelerate outsourcing of their system IP needs to Arteris in order to accelerate their products' time to market, reduce their own costs, and increase their operating efficiencies. Nick will cover these impacts more when he discusses our guidance.

With that, I'd like to turn it over to Nick to discuss our financial results in more detail.

Speaker 2

Thank you, Charlie, and good afternoon, everyone. As I review our second quarter results today, please note that I'll be referring to GAAP as well as non-GAAP metrics. The reconciliation of GAAP to non-GAAP financials is included in today's earnings release, which is available on our website. Also, as a reminder, I will be referring to the Q2 2025 earnings presentation, which can be found on the Investor Relations section of our company's website under the Events and Presentations tab. We had a strong second quarter characterized by meeting or beating our guidance on all key financial metrics. Turning to slide five of the presentation, total revenue for the second quarter was $16.5 million, up 13% year over year, and at the top end of our guidance range.

At the end of the second quarter, annual contract value, or ACV, plus royalties was $69.1 million, up 15% year over year, above the midpoint of our guidance range, our record high for the company. Remaining performance obligations, or RPO, at the end of the second quarter were $99.3 million, representing a 28% year-over-year increase, once again a new high. Non-GAAP gross profit for the quarter was $15 million, representing a gross margin of 91%. GAAP gross profit in the quarter was $14.8 million, representing a gross margin of 89%. Now turning to slide six, non-GAAP operating expense in the quarter was $18.6 million, roughly flat sequentially, and 10% higher year over year. We continue to scale investments in our R&D and field application engineering teams that drive technology innovations and solution support. Total GAAP operating expense for the second quarter was $23 million, representing a 12% year-over-year increase.

As we look ahead, we plan to focus spending on strategically critical areas, in particular to help drive new product development, enhance customer support, and expand the geographic and key account reach of our global sales team. We believe that these ongoing investments can help accelerate our top-line growth in the coming years. At the same time, we are delivering operating leverage by controlling our G&A spending, which has remained broadly flat on a non-GAAP basis for approximately three years. Non-GAAP operating loss in the quarter was $3.5 million, in line with our guidance and flat year over year. GAAP operating loss for the second quarter was $8.2 million, compared to a loss of $7.4 million in the prior year period. Non-GAAP net loss for the quarter was $4.4 million, or diluted net loss per share of $0.11, based on approximately 41.8 million weighted average diluted shares outstanding.

GAAP net loss for the quarter was $9.1 million, or diluted net loss per share of $0.22. Moving to slide seven and turning to the balance sheet and cash flow, we ended the quarter with $53.9 million in cash, cash equivalents, and investments and have no financial debt. Free cash flow, which includes capital expenditure, was negative $2.8 million for the second quarter, approximately at the midpoint of our guidance range. I would now like to turn to the outlook for our third quarter and the full year 2025 and refer now to slide eight. For the third quarter of 2025, we expect ACV plus royalties of $69.5 million to $72.5 million, revenue of $16.8 million to $17.2 million, with non-GAAP operating loss of $3 million to $4 million, and non-GAAP free cash flow of $0.5 million to $3.5 million.

For the full year 2025, our guidance is as follows: ACV plus royalties to exit 2025 at $72 million to $78 million, revenue of $66 million to $70 million, non-GAAP operating loss of between $10.5 million to $15.5 million, and non-GAAP free cash flow of $1 million to $7 million. Our OpEx is currently running higher than previously expected, predominantly as a result of the weaker U.S. dollar, especially against the euro. Although the U.S. dollar has strengthened somewhat in recent days, in assessing our non-GAAP operating loss and guidance, we have assumed that the recent prevailing foreign exchange rates remain at these levels for the remainder of 2025. Despite the near-term impacts of foreign exchange fluctuations, we remain encouraged by our strong deal execution, witnessed by the 28% year-over-year growth in RPO at the end of the second quarter.

Reiterating the point raised earlier by Charlie, we are seeing promising signs of accelerated interest by some major customers to increase their outsourcing of system IP products to Arteris. With that, I will turn the call back to the operator for the Q&A portion of our call. Operator.

Speaker 5

Thank you. Ladies and gentlemen, we will now begin the question and answer session. Should you have a question, please press the star, followed by the number one on your touch-tone phone. You will hear a prompt that your hand has been raised. Should you wish to decline from the polling process, please press the star, followed by the number two. If you are using a speakerphone, please lift the handset before pressing any keys. One moment, please, for your first question. Your first question comes from the line of Josh Buchalter from TD Cowen. Your line is now open. Please go ahead.

Hey, guys, thank you for taking my questions, and congrats on the results on the AMD announcement yesterday. I wanted to ask about that. Any details you can share on the scope? The press release named pretty much all of their products. I believe AMD had been an existing partner of yours. Maybe you could talk through how they're using your IP, and they've been providing chiplets for a while. What are you guys bringing to the table, and what led them to need to use you guys more expansively going forward? Thank you.

Speaker 2

I don't know whether we've lost Charlie. Charlie, you're on mute.

Speaker 6

Apologies. Sorry, everyone. I have you. In February, we announced the FlexGen product, which basically allows higher levels of productivity and also some advantages in PPA in terms of wire length. AMD extensively evaluated this product, including some benchmarks against competitive alternatives, and they basically chose that as the best product for them going forward. What we bring to the table is the new innovative FlexGen technology, and you know, AMD basically decided to apply it to a variety of products, including AI data center chiplets.

Thank you. For my follow-up, how should we think about this layering into the model from a timeline and magnitude perspective? I believe FlexGen has an ASP that's up 30% gen to gen, so you know, how meaningful can this be to the model? Thank you, and congrats again.

Speaker 2

Charlie, should I speak to that one?

Speaker 6

Yeah, please.

Speaker 2

Because I remember what number is questioning.

Speaker 6

Yes, so hi, Josh. Thanks for joining. Great to speak to you, Ian. We do secure a fairly decent number of what we refer to as whale deals, major deals in a year. This is one of those. When we put our guidance out at the end of the first quarter, this deal was already in the works. This has been in the works for many months. It was already baked into guidance at that point. I wouldn't want you to think this is the only big deal we have. We have one or two every quarter, major deals. This was already contemplated when we guided previously. It's very helpful, though.

Okay, I will leave it there, and thank you, and congratulations again.

Speaker 5

Your next question comes from the line of Kevin Garrigan from Rosenblatt Securities. Your line is now open. Please go ahead.

Yeah, hey, Charlie, Nick, congrats on the solid results. I was just wondering, can you comment on whether the decision by AMD was because they're looking to disband their NoC internal team, or if this was more surrounding just not being able to hit performance metrics, so they're looking for another solution?

Speaker 6

Not at all. As we mentioned, FlexGen is going to work with AMD's Infinity Fabric, which is their cache coherent solutions, which is made internally. Basically, the decision that AMD came to is that they are going to continue to use their very capable cache coherent fabric and that they are going to augment that with the Arteris technology for their non-coherent applications. It's a mix and match approach.

Got it. Okay, that makes sense. As a follow-up, you know, you guys previously noted about 20 customers were experimenting with FlexGen, and you talked about how large customers are looking to accelerate adoption of Arteris product. I mean, is there anything else that you guys can do to get these customers over the finish line, or are you pretty much just kind of waiting in the wings for them to make a decision?

Yeah, I mean, FlexGen evolves, in certain senses, changes in methodologies. Some of these evaluations are faster than others. There's a fair number of FlexGens in the wild, more than, as we said, more than two dozen. We anticipate that they're going to result in sales starting in the second half, in addition to the AMD deal.

Okay, great. I appreciate the call.

Speaker 2

I'll add something really quick, Kevin. This is Nick again. Welcome to the call. Thank you for joining. The validation by such a great company as AMD on this technology will certainly be helpful to our calls.

Yeah, no, I completely agree. I mean, the pioneer of the chiplet era is huge. Okay, perfect. I appreciate the caller. Thanks, guys.

Speaker 5

As a reminder, if you wish to ask a question, please press star one. For your next question, it'll come from the line of Gus Richard from Northland. Your line is now open. Please go ahead.

Yes, thanks for taking the question. Just in terms of, I'm sorry to keep on asking about AMD, is this primarily for, you know, chiplet implementations or heterogeneous implementations?

Speaker 6

I think it's going to be used in a variety of products. One of the ones that is certainly going to be used is on AI, data center AI-oriented chiplets, chiplet SoCs. You know, it's a multi-license deal, and so it's going to be used on a variety of products. Chiplets are certainly one of them.

Got it. Can you give us a little bit of an update on sort of how many heterogeneous chiplet projects you see out there now?

What we see, and what a lot of people see, is a little bit different. There's about 600 to 700 SoCs out there. At this time, we're seeing probably 30 projects right now. There's probably more than that, but what we see is about 30. It's about 5% of the total. We are anticipating that over the next couple of years, chiplet projects are going to be probably 30% of the overall SoC design starts. Today, we see maybe 5% of that number.

Okay. That's chiplets in general, not heterogeneous chiplets.

That's not your skin of question because homogeneous chiplets have been in production for a while, right? This would be more in the heterogeneous chiplet category.

Got it. One for you, Nick, just an algo. Just looking at RPO and a couple of other things, it looks like book-to-bill was probably north of 1.5 in the quarter. Is that a fair guess?

Speaker 2

Yeah, I don't really monitor book-to-bill specifically, and I certainly wouldn't comment on that one on Gus. It is a very positive indicator to have your leading indicator of growth, which is the way we characterize RPO, and essentially is our backlog of future revenue, to grow to nearly $100 million and 28% year over year is a great outcome.

Got it. Thanks so much.

Speaker 5

There are no further questions at this time. Please continue, Mr. Charlie Janac.

Speaker 6

Yes. We'd like to thank you for your interest in Arteris. We look forward to meeting with you in the upcoming investor conferences that we're participating in through the next couple of months. We look forward to updating you all on our business progress in the quarters to come. Thank you very much for your support.